Vergoeding 2018-2022 voor ATC-subgroep J05AP : Antivirale middelen voor behandeling van hcv-infecties
- Raming voor de totale Zvw-populatie
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| J05AP01 Ribavirine | 85.125 | 75.357 | 37.675 | 12.925 | 8.866 |
| J05AP05 Simeprevir | 50.033 | . | . | . | . |
| J05AP07 Daclatasvir | 838.270 | 11.424 | . | . | . |
| J05AP08 Sofosbuvir (Sovaldi ®) | 2.240.200 | 197.790 | 189.850 | 100.710 | 77.960 |
| J05AP09 Dasabuvir | 4.186 | . | . | . | . |
| J05AP51 Sofosbuvir met ledipasvir (Harvoni ®) | 7.163.400 | 1.090.200 | 277.360 | 151.400 | 112.070 |
| J05AP53 Ombitasvir met paritaprevir en ritonavir | 84.546 | . | . | . | . |
| J05AP54 Elbasvir met grazoprevir (Zepatier ®) | 1.111.800 | 1.713.100 | 1.178.200 | 580.340 | 411.580 |
| J05AP55 Sofosbuvir met velpatasvir (Epclusa ®) | 14.334.200 | 5.040.800 | 2.126.600 | 1.793.500 | 2.133.400 |
| J05AP56 Sofosbuvir met velpatasvir en voxilaprevir (Vosevi ®) | 511.840 | 729.290 | 299.300 | 436.330 | 548.230 |
| J05AP57 Glecaprevir met pibrentasvir (Maviret ®) | 10.556.200 | 9.726.300 | 7.323.000 | 7.589.200 | 6.150.500 |
| Totaal | 36.979.800 | 18.584.261 | 11.431.985 | 10.664.405 | 9.442.606 |